Cargando…
The choice of test in phase II cancer trials assessing continuous tumour shrinkage when complete responses are expected
Traditionally, phase II cancer trials test a binary endpoint formed from a dichotomisation of the continuous change in tumour size. Directly testing the continuous endpoint provides considerable gains in power, although also results in several statistical issues. One such issue is when complete resp...
Autores principales: | Wason, James MS, Mander, Adrian P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4668774/ https://www.ncbi.nlm.nih.gov/pubmed/22179821 http://dx.doi.org/10.1177/0962280211432192 |
Ejemplares similares
-
Minimizing the Maximum Expected Sample Size in Two-Stage Phase II Clinical Trials with Continuous Outcomes
por: Wason, James M. S., et al.
Publicado: (2012) -
Using continuous data on tumour measurements to improve inference in phase II cancer studies
por: Wason, James MS, et al.
Publicado: (2013) -
Improving phase II oncology trials using best observed RECIST response as an endpoint by modelling continuous tumour measurements
por: Lin, Chien‐Ju, et al.
Publicado: (2017) -
Using continuous data on tumour measurements to improve inference in phase II cancer studies
por: Wason, James, et al.
Publicado: (2013) -
Optimal multistage designs for randomised clinical trials with continuous outcomes
por: Wason, James MS, et al.
Publicado: (2012)